SG Americas Securities
RCUS icon

SG Americas Securities’s Arcus Biosciences RCUS Stock Holding History

SG Americas Securities’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$908K Sell
42,055
-3,433
-8% -$74.1K ﹤0.01% 1815
2025
Q4 		$1.08M Buy
45,488
+12,714
+39% +$259K ﹤0.01% 1943
2025
Q3 		$446K Buy
32,774
+5,412
+20% +$56.3K ﹤0.01% 2203
2025
Q2 		$223K Buy
27,362
+17,111
+167% +$146K ﹤0.01% 2200
2025
Q1 		$80K Sell
10,251
-18,246
-64% -$212K ﹤0.01% 3113
2024
Q4 		$424K Sell
28,497
-1,572
-5% -$25.7K ﹤0.01% 1485
2024
Q3 		$460K Sell
30,069
-99,223
-77% -$1.56M ﹤0.01% 1759
2024
Q2 		$1.97M Buy
129,292
+120,650
+1,396% +$1.95M 0.01% 959
2024
Q1 		$163K Sell
8,642
-11,926
-58% -$206K ﹤0.01% 2132
2023
Q4 		$393K Buy
+20,568
New +$329K ﹤0.01% 1636
2023
Q2 		– Sell
-12,184
Closed -$222K – 3002
2023
Q1 		$222K Sell
12,184
-19,605
-62% -$375K ﹤0.01% 2345
2022
Q4 		$657K Buy
+31,789
New +$875K 0.01% 1308
2022
Q3 		– Sell
-37,557
Closed -$952K – 3482
2022
Q2 		$952K Sell
37,557
-56,629
-60% -$1.39M 0.01% 1344
2022
Q1 		$2.97M Buy
94,186
+68,297
+264% +$2.29M 0.02% 669
2021
Q4 		$1.05M Sell
25,889
-1,201
-4% -$46.6K 0.01% 1618
2021
Q3 		$945K Buy
+27,090
New +$843K ﹤0.01% 1964
2021
Q2 		– Sell
-7,201
Closed -$202K – 3171
2021
Q1 		$202K Sell
7,201
-4,668
-39% -$162K ﹤0.01% 2676
2020
Q4 		$308K Sell
11,869
-20,657
-64% -$500K ﹤0.01% 2345
2020
Q3 		$557K Buy
32,526
+17,863
+122% +$399K ﹤0.01% 1559
2020
Q2 		$363K Buy
14,663
+2,965
+25% +$80K ﹤0.01% 2372
2020
Q1 		$162K Buy
+11,698
New +$145K ﹤0.01% 2660
2019
Q2 		– Sell
-8,782
Closed -$110K – 3353
2019
Q1 		$110K Buy
+8,782
New +$95.3K ﹤0.01% 3001

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

SG Americas Securities's RCUS Position: Q1 2026 in Review

SG Americas Securities reduced its Arcus Biosciences (RCUS) stake by 7.5% in Q1 2026, selling an estimated $74.1K and leaving 42,055 shares worth $908K. The position accounts for ﹤0.01% of the portfolio, ranked #1815.

SG Americas Securities first reported a position in RCUS in Q1 2019 and has held it in 22 quarters since. The position peaked at $2.97M in Q1 2022. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • SG Americas Securities held 42,055 shares of Arcus Biosciences worth $908K as of Q1 2026.
  • SG Americas Securities sold 3,433 Arcus Biosciences shares in Q1 2026, an estimated $74.1K.
  • Arcus Biosciences made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #1815 holding.
  • SG Americas Securities first reported a position in Arcus Biosciences in Q1 2019 and has held it in 22 quarters since.
  • SG Americas Securities's Arcus Biosciences position peaked at $2.97M in Q1 2022.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.